| pubmed-article:17318877 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17318877 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:17318877 | lifeskim:mentions | umls-concept:C0006826 | lld:lifeskim |
| pubmed-article:17318877 | lifeskim:mentions | umls-concept:C0029277 | lld:lifeskim |
| pubmed-article:17318877 | lifeskim:mentions | umls-concept:C0018270 | lld:lifeskim |
| pubmed-article:17318877 | lifeskim:mentions | umls-concept:C0935882 | lld:lifeskim |
| pubmed-article:17318877 | lifeskim:mentions | umls-concept:C0052591 | lld:lifeskim |
| pubmed-article:17318877 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:17318877 | pubmed:dateCreated | 2007-2-28 | lld:pubmed |
| pubmed-article:17318877 | pubmed:abstractText | Substantial evidence supports a direct role of ornithine decarboxylase (ODC) in the development and maintenance of human tumors. Although antisense oligonucleotide therapy targeting various genes are useful for cancer treatment, 1 of the major limitations is the problem of delivery. A novel antisense oligonucleotide delivery method is described that allows prolonged sustainment and release of ODC antisense oligonucleotides in vivo using atelocollagen. | lld:pubmed |
| pubmed-article:17318877 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17318877 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17318877 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:17318877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17318877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17318877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17318877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17318877 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17318877 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:17318877 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:17318877 | pubmed:author | pubmed-author:ItohHiroshiH | lld:pubmed |
| pubmed-article:17318877 | pubmed:author | pubmed-author:NemotoTakahir... | lld:pubmed |
| pubmed-article:17318877 | pubmed:author | pubmed-author:SeyamaYousuke... | lld:pubmed |
| pubmed-article:17318877 | pubmed:author | pubmed-author:KubotaShunich... | lld:pubmed |
| pubmed-article:17318877 | pubmed:author | pubmed-author:NakazawaKunih... | lld:pubmed |
| pubmed-article:17318877 | pubmed:author | pubmed-author:SanoAkihikoA | lld:pubmed |
| pubmed-article:17318877 | pubmed:author | pubmed-author:NagaiYutakaY | lld:pubmed |
| pubmed-article:17318877 | pubmed:author | pubmed-author:NagaharaShunj... | lld:pubmed |
| pubmed-article:17318877 | pubmed:author | pubmed-author:HataTomokoT | lld:pubmed |
| pubmed-article:17318877 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17318877 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:17318877 | pubmed:volume | 109 | lld:pubmed |
| pubmed-article:17318877 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17318877 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17318877 | pubmed:pagination | 993-1002 | lld:pubmed |
| pubmed-article:17318877 | pubmed:meshHeading | pubmed-meshheading:17318877... | lld:pubmed |
| pubmed-article:17318877 | pubmed:meshHeading | pubmed-meshheading:17318877... | lld:pubmed |
| pubmed-article:17318877 | pubmed:meshHeading | pubmed-meshheading:17318877... | lld:pubmed |
| pubmed-article:17318877 | pubmed:meshHeading | pubmed-meshheading:17318877... | lld:pubmed |
| pubmed-article:17318877 | pubmed:meshHeading | pubmed-meshheading:17318877... | lld:pubmed |
| pubmed-article:17318877 | pubmed:meshHeading | pubmed-meshheading:17318877... | lld:pubmed |
| pubmed-article:17318877 | pubmed:meshHeading | pubmed-meshheading:17318877... | lld:pubmed |
| pubmed-article:17318877 | pubmed:meshHeading | pubmed-meshheading:17318877... | lld:pubmed |
| pubmed-article:17318877 | pubmed:meshHeading | pubmed-meshheading:17318877... | lld:pubmed |
| pubmed-article:17318877 | pubmed:meshHeading | pubmed-meshheading:17318877... | lld:pubmed |
| pubmed-article:17318877 | pubmed:meshHeading | pubmed-meshheading:17318877... | lld:pubmed |
| pubmed-article:17318877 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17318877 | pubmed:articleTitle | Single-injection ornithine decarboxylase-directed antisense therapy using atelocollagen to suppress human cancer growth. | lld:pubmed |
| pubmed-article:17318877 | pubmed:affiliation | Department of Physiological Chemistry and Metabolism, Graduate School of Medicine, University of Tokyo, Tokyo, Japan. | lld:pubmed |
| pubmed-article:17318877 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17318877 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17318877 | lld:pubmed |
